Keros Therapeutics (KROS) EBT Margin (2019 - 2025)
Keros Therapeutics (KROS) posted EBT Margin of 13284.57% for Q4 2025, down 21456.91% on a QoQ basis from 61.63% in Q3 2025, and down 1178142.0% year-over-year from N/an in Q4 2024.
Keros Therapeutics (KROS) EBT Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics' EBT Margin history runs 6 years deep, the most recent figure standing at 13284.57% for Q4 2025.
- Quarterly EBT Margin fell 1178142.0% year-over-year to 13284.57% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 37.71% (up 536230.0% YoY) and the FY2025 annual result came in at 37.68%, up 530678.0% from the prior year.
- EBT Margin was 13284.57% for Q4 2025 at Keros Therapeutics, down from 61.63% in the prior quarter.
- Across five years, EBT Margin topped out at 75.03% in Q1 2025 and bottomed at 961000.0% in Q3 2023.
- A 5-year average of 90766.93% and a median of 7393.87% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin surged 94735155 bps — and 2025, when it slumped 1178142 bps.
- Keros Therapeutics' EBT Margin stood at 27.6% in 2021, then slumped by 387 bps to 134.37% in 2022, then slumped by 23619 bps to 31870.63% in 2023, then soared by 95 bps to 1503.16% in 2024, then plunged by 784 bps to 13284.57% in 2025.
- Business Quant data shows KROS's EBT Margin at 13284.57% in Q4 2025, 61.63% in Q3 2025, and 181.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - | -13,284.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13,284.57% |
| Sep 30, 2025 | -61.63% |
| Jun 30, 2025 | -181.19% |
| Mar 31, 2025 | 75.03% |
| Dec 31, 2024 | -1,503.16% |
| Sep 30, 2024 | -13,648.45% |
| Mar 31, 2024 | -51,944.58% |
| Dec 31, 2023 | -31,870.63% |
| Sep 30, 2023 | -961,000.00% |
| Mar 31, 2022 | -134.37% |
| Dec 31, 2021 | -27.60% |
| Jun 30, 2021 | -15,622.00% |
| Dec 31, 2019 | -110.04% |
| Sep 30, 2019 | -141.96% |
| Jun 30, 2019 | -114.12% |
| Mar 31, 2019 | -127.32% |